Email ID
Password
Scrip   
Ligand acquires Neurogen in $11 million deal
25 August 2009
Christopher Spillane

Ligand Pharmaceuticals is to buy Neurogen in an $11 million stock deal that rescues the cash-stricken neurological and psychiatric drug developer.

The move gives Ligand access to an acute and chronic pain partnership with Merck & Co, pipeline products, drug discovery resources and around...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36